Skip to main content
. 2014 Feb;58(2):923–930. doi: 10.1128/AAC.02238-13

TABLE 1.

MICs for Escherichia coli strainsa

Compound (MIC unit) MIC for strainb:
W3110 BC202 ΔmdfA mutant BC202 M ΔemrE mutant BC202E ΔacrB mutant BC202A
SDS (%) >1 >1 >1 >1 >1 >1 0.5 0.06
CAM (μg/ml) 6.0 6.0 3.0 3.0 6.0 6.0 0.4 0.4
BC (μg/ml) 25 6.3 6.3 6.3 12.5 3.1 0.8 0.2
NA (μg/ml) 6.0 3.0 6.0 3.0 6.0 1.6 3.0 0.4
CTAB (μg/ml) 12.5 6.3 6.3 3.1 6.3 1.6 1.6 1.6
MV (μg/ml) 100 25 100 25 25 12.5 100 25
Acr (μg/ml) 100 12.5 50 6.3 25 6.3 6.3 0.8
EthBr (μg/ml) 400 25 200 12.5 200 12.5 3.1 0.8
Erythro (μg/ml)c 100 50 100 50 100 50 6.3 3.1
Cipro (ng/ml)c 5.0 2.5 5.0 2.5 5.0 2.5 1.25 0.3
Norflox (ng/ml)c 40 20 40 20 40 20 20 5.0
Ox (μg/ml) 400 200 ND ND ND ND 25 3.1
Clox (μg/ml) 400 200 ND ND ND ND 25 3.1
Pip (μg/ml) 2 0.5 ND ND ND ND 0.25 0.03
a

W3110 (parent), BC202, and mutants with efflux pump mutations in either the W3110 (ΔmdfA, ΔemrE, and ΔacrB) or BC202 (BC202M, BC202E, and BC202A) background strain were grown in liquid culture in the presence of a series of dilutions of the indicated compounds. Abbreviations: SDS, sodium dodecyl sulfate; CAM, chloramphenicol; BC, benzalkonium chloride; NA, nalidixic acid; CTAB, cetyl trimethyl ammonium bromide; MV, methyl viologen; Acr, acriflavine hydrochloride; EthBr, ethidium bromide; Erythro, erythromycin; Cipro, ciprofloxacin; Norflox, norfloxacin; Ox, oxacillin; Clox, cloxacillin; Pip, piperacillin; ND, not determined.

b

In strain BC202, increased sensitivity to the indicated compounds is shown in italic. In strains BC202M, BC202E, and BC202A, additive or synergistic effects are shown in bold.

c

BC202 was not sensitive to erythromycin, ciprofloxacin, and norfloxacin on plates (Fig. 1 and data not shown) but was slightly sensitive in liquid culture.